TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33637001
Drug: Reboxetine (noradrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (noradrenaline reuptake inhibitor)
Study: 39673452
Drug: Dupilumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab treatment
Study: 39165177
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment
Study: 35202621
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg) three times weekly for 3 months along with standard treatment
Study: 35977072
Drug: LY2409021 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2409021 (100 mg single dose)
Study: 32939849
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil therapy (administered two weeks before surgery)
Study: 34738855
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg/day for one week, then titrated to 60 mg/day for 12 weeks)
Study: 34738855
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule daily for one week, then two capsules daily for 12 weeks)
Study: 34028826
Drug: Probiotics (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (one capsule/day for 30 days)
Study: 34028826
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule/day for 30 days)
Study: 35790574
Drug: Adalimumab (HUMIRA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (HUMIRA) injection
Study: 34190716
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg PO daily for 2 weeks
Study: 35857037
Drug: Acipimox and
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox and conventional treatment
Study: 35702828
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone (8 mg/2 mg to 24 mg/6 mg per day; flexible take-home dosing)
Study: 35702828
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (≈60-120 mg/day; closely supervised)
Study: 35702828
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone
Study: 32349893
Drug: Açaí juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Açaí juice (200 mL/day for 4 weeks)
Study: 32349893
Drug: Juçara juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juçara juice (200 mL/day for 4 weeks)
Study: 33108244
Drug: rhG-CSF combined
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhG-CSF combined with minimal-dose Dec (G-Dec group: 100 µg/m2 of rhG-CSF on days 0-5 and 5 mg/m2 of Dec on days 1-5)
Study: 33108244
Drug: no intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: no intervention (non-G-Dec group)
Study: 37623203
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg)
Study: 32591498
Drug: Six repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six repeated ketamine infusions
Study: 33607775
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection combined with sodium nitroprusside
Study: 35620919
Drug: α-difluoromethylornithine (DFMO)
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: α-difluoromethylornithine (DFMO) administered orally at a dosage of 500 mg/m2/day for up to 5 years.
Study: 35620919
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) administered orally for up to 5 years.
Study: 32271671
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (CT+E)
Study: 34614209
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (E)
Study: 33601378
Drug: Emollient plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient plus cream (EC; Dermoflan®) applied once daily for 2 months
Study: 33044990
Drug: Tobacco Cessation
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco Cessation on Prescription (TCP)
Study: 34303447
Drug: Community Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Care (CC)
Study: 33663235
Drug: Conventional glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose-lowering therapy
Study: 33724542
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) 50 mg/week
Study: 33662902
Drug: Lung-protective ventilation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-protective ventilation (LPV) with tidal volume 6 ml/kg PBW + PEEP 7 cmH2O
Study: 33662902
Drug: Nonprotective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprotective ventilation (control group) with tidal volume 9 ml/kg PBW without PEEP
Study: 34310276
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Pain (CBT‐P)
Study: 36343068
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional physical therapy treatment)
Study: 36410806
Drug: Standard dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysate magnesium concentration of 0.50 mmol/L
Study: 35279301
Drug: Imported dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported dental implants (control group)
Study: 33200812
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the morning for 6 weeks
Study: 33200812
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the evening for 6 weeks
Study: 33200812
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of the drug
Study: 33200812
Drug: Morning vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning vs Evening drug administration
Study: 35101110
Drug: Pars plana
Normalized name: Planatus occidentalis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pars plana vitrectomy, off-label subretinal TPA up to 25 μg in 0.25 ml, intravitreal 20% sulfahexafluoride gas, and intravitreal aflibercept.
Study: 35101110
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept monotherapy.
Study: 33738656
Drug: Two courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Study: 33738656
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Study: 32723670
Drug: SPN-812 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 100 mg/day
Study: 34608329
Drug: Islatravir 62
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 62 mg
Study: 37869523
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment
Study: 35142582
Drug: Daratumumab-based triplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab-based triplet therapies (VGPR or better)
Study: 33216196
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 10 mg/kg/day, orally
Study: 35981821
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation)
Study: 34338759
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (SAPT)
Study: 33411910
Drug: 12 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g/day of fructooligosaccharide (FOS) for 3 months
Study: 34690144
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg
Study: 32207575
Drug: 25 mg/ml
Normalized name: hemin 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/ml tranexamic acid (TXA)
Study: 36765312
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control condition)
Study: 37661604
Drug: Cryomodulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryomodulation treatment (10-min controlled cooling)
Study: 37661604
Drug: Cryomodulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryomodulation treatment
Study: 34241762
Drug: 17-estradiol (E2)
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17-estradiol (E2) (10 µg/g body weight)
Study: 34241762
Drug: Blank (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank (no injection)
Study: 34962574
Drug: MAO-B inhibitor
Normalized name: MAO B Inhibitors, dopaminergic anti-parkinson drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAO-B inhibitor
Study: 34962574
Drug: COMT inhibitor
Normalized name: levodopa, decarboxylase inhibitor and COMT inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMT inhibitor
Study: 34962574
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist vs MAO-B inhibitors
Study: 34962574
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist and MAO-B inhibitors
Study: 33085647
Drug: Cerebellar intermittent
Normalized name: Sus scrofa cerebellum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebellar intermittent theta burst stimulation (iTBS), 10-day treatment
Study: 34689142
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without treatment)
Study: 32266595
Drug: Independent risk
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent risk factors identified: age, race, T stage, N stage, M stage, surgery, radiotherapy, chemotherapy, marital status.
Study: 34836235
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of PXN
Study: 34784246
Drug: Lumbar spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar spine treatment only (LBO group)
Study: 34784246
Drug: Lumbar spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar spine and hip treatments (LBH group)
Study: 35737076
Drug: Robot-Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-Assisted Therapy (RT)
Study: 34293643
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT)
Study: 35984478
Drug: CGM-guided insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGM-guided insulin adjustment
Study: 32950830
Drug: Montelukast combined
Normalized name: montelukast, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast combined with intranasal mometasone furoate (Group I)
Study: 32950830
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone furoate alone (Group II)
Study: 36148627
Drug: Milky lotions
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milky lotions containing mevalonolactone (MVL)
Study: 35060943
Drug: Psyllium (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (6 g/d)
Study: 32827122
Drug: NHF 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHF 20 L/min
Study: 32827122
Drug: NHF 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHF 50 L/min
Study: 35526858
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/day)
Study: 34118065
Drug: Intensified support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified support by clinical pharmacologists/pharmacists for patients and treatment team
Study: 34118065
Drug: Advanced medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced medication reviews performed by clinical pharmacologists/pharmacists
Study: 34118065
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral anticancer drug regimen
Study: 34118065
Drug: Drug-drug or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-drug or drug-food interactions
Study: 32349070
Drug: Preoperative angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative angiotensin system inhibitors
Study: 32349070
Drug: Postoperative angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative angiotensin system inhibitors
Study: 32349070
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no angiotensin system inhibitors preoperatively)
Study: 32349070
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no angiotensin system inhibitors postoperatively)
Study: 33065080
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual antiplatelet therapy (DAPT; ticagrelor and aspirin) followed by 23-month ticagrelor monotherapy
Study: 34528897
Drug: iGAM app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: iGAM app intervention group (photographed gums weekly for 8 weeks)
Study: 33787834
Drug: Revacept 160
Normalized name: Revacept
DrugBank: PR-15 (DB06037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revacept 160 mg
Study: 39018515
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy
Study: 34929392
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (23 g/d fiber)
Study: 34929392
Drug: Minimally-fermented sugarcane
Normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally-fermented sugarcane bagasse (33 g/d fiber)
Study: 34929392
Drug: Fiber combination
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber combination (sugarcane bagasse with resistant starch, ∼45 g/d fiber)
Study: 33802283
Drug: Creatine (CRE)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (CRE) supplementation at 0.3 g·kg−1·d−1 for seven days
Study: 36203818
Drug: Intravenous Patient-Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Patient-Controlled Opioid Analgesia (PCIA)
Study: 34002265
Drug: Hexvix® TURB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexvix® TURB with immediate ICT only (n=67, 40 mg Mitomycin)
Study: 34002265
Drug: white-light TURB
Normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: white-light TURB with immediate ICT followed by maintenance ICT (n=62, 20 mg Mitomycin weekly for 6 weeks, then 20 mg/month for 6 months)
Study: 36269714
Drug: 3HR (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HR (three months of daily isoniazid plus rifampicin)
Study: 36269714
Drug: 3HP (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP (three months of once-weekly isoniazid plus rifapentine)
Study: 36269714
Drug: 4R (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4R (four months of daily rifampicin)
Study: 33713409
Drug: Varenicline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline treatment
Study: 37256485
Drug: Active ophthalmic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ophthalmic drops (Latilactobacillus sakei)
Study: 37256485
Drug: Placebo ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic drops
Study: 37256485
Drug: Active oral
Normalized name: Factive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oral capsules (Latilactobacillus sakei)
Study: 37256485
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules
Study: 33660668
Drug: Nonclinic-based adolescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonclinic-based adolescent behavioral weight control treatment delivered by YMCA coaches
Study: 36297022
Drug: Astragalosides supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalosides supplementation (4 mg per day for 7 days)
Study: 32482519
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg SR orally twice daily)
Study: 32825990
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment (5 sessions over 8 weeks)
Study: 34768520
Drug: Placebo (simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (simulated pulsed shortwave therapy)
Study: 34218684
Drug: Repeated ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeated ivermectin mass drug administrations
Study: 34606832
Drug: 1.0% asivatrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% asivatrep cream
Study: 33631066
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg, single intravenous infusion, with a possible second dose 8 to 24 hours later)
Study: 34147041
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg capsules of Berberis vulgaris extract, twice daily for 4 weeks
Study: 34147041
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of starch capsules (placebo), twice daily for 4 weeks
Study: 32223373
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and MEDs (COMB)
Study: 34727951
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotic prophylaxis (AP)
Study: 32947390
Drug: Umezu polyphenols
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umezu polyphenols (800 mg/day for 12 weeks)
Study: 35215483
Drug: School-based and
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based and family-based interventions with monthly monitoring for two consecutive semesters
Study: 33417728
Drug: Other WMTs
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other WMTs in cingulum, cerebral and cerebellar peduncle, internal capsule, and corpus callosum
Study: 33865928
Drug: ENGAGE (engagement-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENGAGE (engagement-focused behavioral therapy)
Study: 33865928
Drug: Consistent medication
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent medication use during behavioral therapy
Study: 32899089
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser therapy
Study: 33344050
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide for 3 months
Study: 33464334
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous thrombolysis (alteplase at 0.6 mg/kg) plus mechanical thrombectomy (n=103)
Study: 33464334
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous thrombolysis plus mechanical thrombectomy
Study: 35320401
Drug: Polyphenol supplement
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol supplement (PPS) containing black tea powder, cocoa powder, and grape juice extract
Study: 34101212
Drug: Maternal thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal thiamine supplementation (10 mg/day)
Study: 34101212
Drug: Maternal thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal thiamine supplementation (0 mg/day)
Study: 34101212
Drug: Maternal thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal thiamine supplementation (1.2 mg/day)
Study: 34101212
Drug: Maternal thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal thiamine supplementation (2.4 mg/day)
Study: 38167019
Drug: Adalimumab monotherapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab monotherapy
Study: 34158840
Drug: Panitumumab-IRDye800 at
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab-IRDye800 at low (50 mg) or high (100 mg) dose
Study: 34158840
Drug: Panitumumab-IRDye800 at
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab-IRDye800 at high (100 mg) dose
Study: 34878625
Drug: LY-CovMab 1200
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CovMab 1200 mg
Study: 34878625
Drug: LY-CovMab 2400
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CovMab 2400 mg
Study: 33492208
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of lansoprazole twice daily for 16 weeks